236 related articles for article (PubMed ID: 33561807)
1. P2Y
Jasmer KJ; Woods LT; Forti KM; Martin AL; Camden JM; Colonna M; Weisman GA
Arch Oral Biol; 2021 Apr; 124():105067. PubMed ID: 33561807
[TBL] [Abstract][Full Text] [Related]
2. P2Y
Woods LT; Camden JM; Khalafalla MG; Petris MJ; Erb L; Ambrus JL; Weisman GA
Oral Dis; 2018 Jul; 24(5):761-771. PubMed ID: 29297959
[TBL] [Abstract][Full Text] [Related]
3. P2Y2 nucleotide receptor up-regulation in submandibular gland cells from the NOD.B10 mouse model of Sjögren's syndrome.
Schrader AM; Camden JM; Weisman GA
Arch Oral Biol; 2005 Jun; 50(6):533-40. PubMed ID: 15848146
[TBL] [Abstract][Full Text] [Related]
4. P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy.
Khalafalla MG; Woods LT; Camden JM; Khan AA; Limesand KH; Petris MJ; Erb L; Weisman GA
J Biol Chem; 2017 Oct; 292(40):16626-16637. PubMed ID: 28798231
[TBL] [Abstract][Full Text] [Related]
5. Cenerimod, a selective S1P
Gerossier E; Nayar S; Froidevaux S; Smith CG; Runser C; Iannizzotto V; Vezzali E; Pierlot G; Mentzel U; Murphy MJ; Martinic MM; Barone F
Arthritis Res Ther; 2021 Nov; 23(1):289. PubMed ID: 34839819
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-7 receptor-α treatment ameliorates newly established Sjögren's-like exocrinopathy in non-obese diabetic mice.
Zhou J; Yu Q
Biochim Biophys Acta Mol Basis Dis; 2018 Jul; 1864(7):2438-2447. PubMed ID: 29680668
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-7 enhances the Th1 response to promote the development of Sjögren's syndrome-like autoimmune exocrinopathy in mice.
Jin JO; Kawai T; Cha S; Yu Q
Arthritis Rheum; 2013 Aug; 65(8):2132-42. PubMed ID: 23666710
[TBL] [Abstract][Full Text] [Related]
8. Early Dry Eye Disease Onset in a NOD.H-2h4 Mouse Model of Sjögren's Syndrome.
Li L; Jasmer KJ; Camden JM; Woods LT; Martin AL; Yang Y; Layton M; Petris MJ; Baker OJ; Weisman GA; Petris CK
Invest Ophthalmol Vis Sci; 2022 Jun; 63(6):18. PubMed ID: 35727180
[TBL] [Abstract][Full Text] [Related]
9. Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndrome.
Yin H; Nguyen CQ; Samuni Y; Uede T; Peck AB; Chiorini JA
Arthritis Res Ther; 2012 Feb; 14(1):R40. PubMed ID: 22369699
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-17 Impairs Salivary Tight Junction Integrity in Sjögren's Syndrome.
Zhang LW; Cong X; Zhang Y; Wei T; Su YC; Serrão AC; Brito AR; Yu GY; Hua H; Wu LL
J Dent Res; 2016 Jul; 95(7):784-92. PubMed ID: 26933138
[TBL] [Abstract][Full Text] [Related]
11. Metformin improves salivary gland inflammation and hypofunction in murine Sjögren's syndrome.
Kim JW; Kim SM; Park JS; Hwang SH; Choi J; Jung KA; Ryu JG; Lee SY; Kwok SK; Cho ML; Park SH
Arthritis Res Ther; 2019 Jun; 21(1):136. PubMed ID: 31164166
[TBL] [Abstract][Full Text] [Related]
12. Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren's syndrome.
Wieczorek G; Bigaud M; Pfister S; Ceci M; McMichael K; Afatsawo C; Hamburger M; Texier C; Henry M; Cojean C; Erard M; Mamber N; Rush JS
Ann Rheum Dis; 2019 Jul; 78(7):974-978. PubMed ID: 30902822
[TBL] [Abstract][Full Text] [Related]
13. Disruption of endothelial barrier function is linked with hyposecretion and lymphocytic infiltration in salivary glands of Sjögren's syndrome.
Cong X; Zhang XM; Zhang Y; Wei T; He QH; Zhang LW; Hua H; Lee SW; Park K; Yu GY; Wu LL
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3154-3163. PubMed ID: 29981359
[TBL] [Abstract][Full Text] [Related]
14. Gluten-free diet modulates inflammation in salivary glands and pancreatic islets.
Haupt-Jorgensen M; Groule V; Reibel J; Buschard K; Pedersen AML
Oral Dis; 2022 Apr; 28(3):639-647. PubMed ID: 33432638
[TBL] [Abstract][Full Text] [Related]
15. B7-H4 Inhibits the Development of Primary Sjögren's Syndrome by Regulating Treg Differentiation in NOD/Ltj Mice.
Zheng X; Wang Q; Yuan X; Zhou Y; Chu H; Wang G; Li X; Wang Y; Wei L; Wang L; Li X
J Immunol Res; 2020; 2020():4896727. PubMed ID: 33062721
[TBL] [Abstract][Full Text] [Related]
16. NOD mouse model for Sjögren's syndrome: lack of longitudinal stability.
Lodde BM; Mineshiba F; Kok MR; Wang J; Zheng C; Schmidt M; Cotrim AP; Kriete M; Tak PP; Baum BJ
Oral Dis; 2006 Nov; 12(6):566-72. PubMed ID: 17054769
[TBL] [Abstract][Full Text] [Related]
17. Marginal Zone B (MZB) Cells: Comparison of the Initial Identification of Immune Activity Leading to Dacryoadenitis and Sialadenitis in Experimental Sjögren's Syndrome.
Peck AB; Ambrus JL
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569583
[TBL] [Abstract][Full Text] [Related]
18. Non-depleting anti-CD4 antibody not only prevents onset but resolves sialadenitis in NOD mice.
Thompson C; Jacobsen H; Pomeranz Krummel D; Nagai K; Cooke A
Autoimmunity; 2004 Dec; 37(8):549-54. PubMed ID: 15763917
[TBL] [Abstract][Full Text] [Related]
19. Low-dose interleukin-2 can improve salivary secretion but not lymphocyte infiltration of salivary glands in a murine model of Sjögren's syndrome.
Wen J; Zhu F; Yu X; Xie H; Li C
BMC Immunol; 2022 Oct; 23(1):49. PubMed ID: 36244973
[TBL] [Abstract][Full Text] [Related]
20. RORγt antagonist suppresses M3 muscarinic acetylcholine receptor-induced Sjögren's syndrome-like sialadenitis.
Tahara M; Tsuboi H; Segawa S; Asashima H; Iizuka-Koga M; Hirota T; Takahashi H; Kondo Y; Matsui M; Matsumoto I; Sumida T
Clin Exp Immunol; 2017 Feb; 187(2):213-224. PubMed ID: 27643385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
